Gangemi v. Arch Oncology, Inc.

CourtDistrict Court, S.D. New York
DecidedMay 26, 2023
Docket1:22-cv-07961
StatusUnknown

This text of Gangemi v. Arch Oncology, Inc. (Gangemi v. Arch Oncology, Inc.) is published on Counsel Stack Legal Research, covering District Court, S.D. New York primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Gangemi v. Arch Oncology, Inc., (S.D.N.Y. 2023).

Opinion

UNITED STATES DISTRICT COURT SOUTHERN DISTRICT OF NEW YORK --------------------------------------------------------------------- x PAULETTE GANGEMI, : : Plaintiff, : : 22-CV-7961 (ALC) -against- : : OPINION AND ORDER ARCH ONCOLOGY, INC., THE BOARD OF : DIRECTORS OF ARCH, AND LAURENCE : BLUMBERG. : : Defendants. x --------------------------------------------------------------------- ANDREW L. CARTER, JR., United States District Judge: This is an action involving Plaintiff Paulette Gangemi (“Plaintiff”) and arising out of Plaintiff’s brief employment with Defendant Arch Oncology, Inc. (“Arch”). Plaintiff brings this action against Arch, the Arch Board of Directors (“Board”), and former Arch CEO Laurence Blumberg (“Dr. Blumberg”) (collectively, “Defendants”), alleging breach of contract, promissory estoppel, fraud, and material misrepresentation. Before the Court is Defendants’ motion to dismiss the Complaint. For the reasons stated herein, Plaintiff is GRANTED leave to file her First Amended Complaint. Defendants’ motion to dismiss Plaintiff’s existing promissory estoppel claim GRANTED. Defendants’ motion to dismiss is otherwise DENIED. BACKGROUND I. Factual Background For the purposes of this motion, the Court takes Plaintiff’s allegations as true and draws all reasonable inferences in her favor. Plaintiff is a Human Resources executive. She was employed by Daiichi Sankyo, Inc. when, in April 2022, she was contacted by a recruiter and interviewed for a position with Defendant Arch. See Compl., ECF No. 3, ¶¶ 13-14. In May 2022, Plaintiff interviewed with Dr. Blumberg, and subsequently in May and June 2022, interviewed with Arch Board members. Plaintiff alleges that Dr. Blumberg and the Board members made representations during the interviews regarding Arch’s financial position and “bright future growth.” Id., at ¶¶ 19, 22-23, 27. Plaintiff claims that her interview with a Board member “led [her] to believe that the

Company and the team was over-performing and further evidence that the Company enjoyed a solid financial position and was well capitalized.” Id., at ¶ 31. On June 27, 2022, Plaintiff was offered the position of Vice President of Human Resources with Arch, and received a detailed offer letter from Arch stating Plaintiff’s employment was “at will.” Id., at ¶ 36; Offer Letter dated June 27, 2022 (“Offer Letter”), Anci Decl., Ex. B, ECF No. 30-2. The Offer Letter detailed a termination clause requiring Plaintiff to execute a release to receive severance. Ex. B. During a conversation with Dr. Blumberg on this date, Dr. Blumberg advised Plaintiff that biotech, and oncology specifically, was “risky,” but he believed Arch had a “very bright future.” Id. Plaintiff accepted the offer on June 28, 2022 and started at Arch on July 25, 2022. Id. On July 11, 2022, Dr. Blumberg informed Plaintiff that a participant in an Arch clinical

trial had died. See Compl., ECF No. 3, at ¶¶ 41-42. On July 16, 2022, Plaintiff was informed that Arch planned to lay off staff. Id., at ¶ 52. On or about July 28, 2022, Plaintiff alleges she was “asked to put a severance plan[] together.” Id., at ¶ 72. On August 25, 2022, Arch leadership further discussed layoffs. Id., at ¶ 120. Plaintiff alleges that she was “constructively terminated” from Arch on August 31, 2022, as a result of Dr. Blumberg’s “actions walling her off from any actions as VP of HR.” Id., at ¶ 128. II. Procedural Background On September 17, 2022, Plaintiff filed this action. See Compl., ECF No. 3. Plaintiff seeks damages totaling in the hundreds of thousands of dollars for severance, COBRA premiums, and salary lost by resigning from her former employer. Id., at ¶¶ 4-6. On January 25, 2023, Defendants filed a motion to dismiss. ECF No. 29. The Court now turns to the motion to dismiss. LEGAL STANDARD

I. 12(b)(6) Motion to Dismiss When deciding a motion to dismiss, the Court must “accept as true all factual statements alleged in the complaint and draw all reasonable inferences in favor of the non-moving party.” McCarthy v. Dun & Bradstreet Corp., 482 F.3d 184, 191 (2d Cir. 2007). However, the Court need not credit “[t]hreadbare recitals of the elements of a cause of action, supported by mere conclusory statements.” Ashcroft v. Iqbal, 556 U.S. 662, 678 (2009) (citing Bell Atl. Corp. v. Twombly, 550 U.S. 544, 555 (2007)). Claims should be dismissed when a plaintiff has not pleaded enough facts that “plausibly give rise to an entitlement for relief.” Id. at 679. A claim is plausible “when the plaintiff pleads factual content that allows the Court to draw the reasonable inference that the defendant is liable for the misconduct alleged.” Id. at 678 (citing Twombly, 550

U.S. at 556). While not akin to a “probability requirement,” the plaintiff must allege sufficient facts to show “more than a sheer possibility that a defendant has acted unlawfully.” Id. (citing Twombly, 550 U.S. at 556). Accordingly, where a plaintiff alleges facts that are “‘merely consistent with’ a defendant’s liability, it ‘stops short of the line between possibility and plausibility of entitlement to relief.’” Id. (quoting Twombly, 550 U.S. at 557). II. 12(b)(6) Motion to Dismiss Pursuant to Rule 9(b), a plaintiff who alleges a fraud claim “must state with particularity the circumstances constituting fraud or mistake.” Fed. R. Civ. P. 9(b). In order to comply with Rule 9(b), the “complaint must: (1) specify the statements that the plaintiff contends were fraudulent, (2) identify the speaker, (3) state where and when the statements were made, and (4) explain why the statements were fraudulent.” Aquino by Convergent Distrib. of Texas, LLC v. Alexander Capital, LP, No. 21 Civ. 1355, 2021 WL 3185533, at *12 (S.D.N.Y. July 27, 2021) (quoting Lerner v. Fleet Bank, N.A., 459 F.3d 273, 290 (2d Cir. 2006)). In addition, a plaintiff

must also “allege facts that give rise to a strong inference of fraudulent intent.” Id. ANALYSIS I. COBRA Plaintiff contends she was terminated without cause, and alleges Defendant Arch failed to pay for Plaintiff’s medical premiums or, alternatively, “to advance her the premiums for the payments required by the Consolidated Omnibus Budget Reconciliation Act of 1985 (“COBRA”) as provided in the Offer Letter.” Compl., ECF No. 3, at ¶¶ 132-133. Plaintiff contends she is entitled to $1,000 per month to cover COBRA premiums, and Defendants’ “failure” to provide this “is a violation of Gangemi’s federally guaranteed rights.” Id. at ¶¶ 133- 134.

However, “COBRA simply requires that employers notify outgoing employees of their right to elect COBRA coverage; it does not obligate employers to pay premiums for any coverage that an employee elects. Terminated and otherwise departing employees must pay their own premiums.” Polito v. Tri-Wire Eng’g Sol., Inc., 699 F. Supp. 2d 480, 489 (E.D.N.Y. 2010). Plaintiff has not alleged Defendant Arch failed to provide notice, or otherwise comply with COBRA. Rather, Plaintiff’s COBRA claim stems from a provision in the Offer Letter. Ex. B. The Offer Letter states that, subject to conditions precedent, Arch would pay Plaintiff’s COBRA premiums for the duration of the severance period. Id. As such, Plaintiff has not stated a COBRA claim independent of her breach of contract claim. The Court now turns to this. II. Breach of Contract A plaintiff asserting a claim for breach of contract must satisfy the following elements:

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McCarthy v. Dun & Bradstreet Corp.
482 F.3d 184 (Second Circuit, 2007)
Foman v. Davis
371 U.S. 178 (Supreme Court, 1962)
Bell Atlantic Corp. v. Twombly
550 U.S. 544 (Supreme Court, 2007)
Ashcroft v. Iqbal
556 U.S. 662 (Supreme Court, 2009)
Israel Alicea Rosado v. Ramon Garcia Santiago
562 F.2d 114 (First Circuit, 1977)
ATSI Communications, Inc. v. Shaar Fund, Ltd.
493 F.3d 87 (Second Circuit, 2007)
Polito v. TRI-WIRE ENGINEERING SOLUTION, INC.
699 F. Supp. 2d 480 (E.D. New York, 2010)
Prince v. Madison Square Garden
427 F. Supp. 2d 372 (S.D. New York, 2006)
Orlander v. Staples, Inc.
802 F.3d 289 (Second Circuit, 2015)
Hanna v. New York Hotel Trades Council
18 Misc. 3d 436 (New York Supreme Court, 2007)
Lerner v. Fleet Bank, N.A.
459 F.3d 273 (Second Circuit, 2006)

Cite This Page — Counsel Stack

Bluebook (online)
Gangemi v. Arch Oncology, Inc., Counsel Stack Legal Research, https://law.counselstack.com/opinion/gangemi-v-arch-oncology-inc-nysd-2023.